Anavex life sciences to present at the h.c. wainwright bioconnect investor conference at nasdaq

New york, april 25, 2023 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) disorders, today announced that christopher u. missling, phd, president and chief executive officer of anavex, will participate in a fireside chat at the h.c. wainwright bioconnect investor conference at nasdaq being held may 2nd, 2023 at 9:30am et at nasdaq world headquarters new york city.
AVXL Ratings Summary
AVXL Quant Ranking